METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS

This Phase 3 trial tests whether survodutide, a weekly injection, can improve liver outcomes in 1590 adults with NASH or MASH cirrhosis. Participants are randomly assigned to receive survodutide or a placebo, along with diet and exercise counseling. The study will track serious l…

This study tests two experimental drugs, ECC4703 and ECC0509, alone or together, in 160 adults with MASH (a type of fatty liver disease). The goal is to see if they can safely reduce liver fat over 12 weeks. Participants will be randomly assigned to receive the drugs or a placebo…

This Phase 3 trial tests whether efimosfermin alfa can improve liver fibrosis in adults with compensated cirrhosis caused by MASH (a fatty liver disease). Participants receive either the drug or a placebo via injection. The main goal is to see if liver scarring improves by at lea…

This phase 3 study tests whether an experimental drug called efimosfermin alfa can prevent serious liver complications in adults with compensated cirrhosis due to MASH (metabolic dysfunction-associated steatohepatitis). Participants receive either the drug or a placebo as a shot …

This early-stage trial is testing an experimental drug called INI-822 to see if it is safe and tolerable. It involves healthy volunteers and people with MASH, a type of fatty liver disease. The study will give different doses of the drug or a placebo to see how the body handles i…

This phase 3 trial tests a drug called efimosfermin alfa in 1250 adults with MASH (a fatty liver disease) and moderate liver scarring. The main goal is to check safety and side effects. Participants will receive either the drug or a placebo, and researchers will monitor liver hea…

This phase 2 trial tests a drug called efimosfermin alfa in 42 adults with liver scarring (cirrhosis) caused by fatty liver disease (MASH). Participants receive either the drug or a placebo as a shot under the skin. The main goal is to check safety and how the drug moves through …

This study tests an experimental drug called ALN-CIDEB in adults with fatty liver conditions (MASLD or MASH). The main goal is to check safety and tolerability, and also to see if the drug can reduce liver fat. About 132 participants will receive either the drug or a placebo. Thi…

This study tests whether a minimally invasive procedure called endoscopic sleeve gastroplasty (ESG), which reduces stomach size by 70%, can help reverse fatty liver disease (MASH) in people with obesity. Researchers will compare ESG plus lifestyle changes to lifestyle changes alo…

This early-stage trial tests an experimental drug called NNC0581-0001 in 48 adults with fatty liver and suspected liver inflammation. Participants receive three monthly injections of either the drug or a placebo. The main goal is to check safety and how the drug moves through the…

This study is testing whether measuring spleen stiffness with a special ultrasound probe can detect advanced liver scarring in people with metabolic fatty liver disease (MASLD). Researchers will follow 500 adults for up to several years to see if the test predicts serious liver p…

This pilot study is testing a new Thermoacoustic Enhanced Ultrasound device to measure fat in the liver. Researchers will compare the device's readings to the gold-standard MRI measurement in 49 adults with fatty liver disease. The goal is to develop a more accessible and afforda…

This early-stage trial is testing a new drug called BI 3804379 in healthy adults to see if it is safe and how the body processes it. About 106 healthy men and women aged 18 to 65 will receive either the drug or a placebo as a shot under the skin. The study focuses on side effects…

This early-phase study tests a new way to use PET scans to measure inflammation in both the liver and brain at the same time. Researchers will scan 12 adults with fatty liver disease using two different tracers (18F-FDG and 18F-DPA-714) to see if the new method can reliably detec…

This early-stage study tests a new drug called ECC4703, being developed for a serious fatty liver condition (MASH). Researchers want to see how taking the drug with or without food changes the amount that gets into the blood. 72 healthy adults will receive a single dose of the dr…

This study looks at how tiny communication points inside liver cells (called MAMs) change in people with a fatty liver disease called MASH. Researchers will collect liver and blood samples from 20 adults having weight-loss surgery. The goal is to understand what goes wrong in the…